Gareth Morgan, Rafael Fonseca, Leif Bergsagel, and Keith Stewart discuss highlights from day two of the Myeloma 2022 meeting, covering topics such as BCL2 inhibitors, T-cell exhaustion, immunotherapy, targeted therapies, combination therapies, minimal residual disease, and the efficacy of Carti therapy in managing melon.

Guests Gareth Morgan, Nina Shah, and Leif Bergsagel discuss the highlights of Myeloma 2017, including MRD's impact on clinical trials, promising results of nelfinavir and proteasome inhibitor combination therapy, advancements in targeted therapies and imaging, and the consensus on primary principles of MM treatment.

Doctors Keith Stewart, Leif Bergsagel, and Gareth Morgan discuss the highlights of Myeloma 2017 meeting, including immunotherapy advances, a new MM subtype, and the use of liquid biopsies. They explore advancements in CAR-T cell therapy and combination immunotherapies, the potential for double hit myeloma, and the importance of molecular diagnostics. The podcast also touches on amyloidosis updates and advancements in multiple myeloma diagnosis and imaging.